Terms: = Head and neck cancer AND MAP2K2, MEK2, 5605, ENSG00000126934, P36507, MKK2, MAPKK2, PRKMK2 AND Prognosis
4 results:
1. Characterization of the genomic alterations in poorly differentiated thyroid cancer.
Lee Y; Moon S; Seok JY; Lee JH; Nam S; Chung YS
Sci Rep; 2023 Nov; 13(1):19154. PubMed ID: 37932340
[TBL] [Abstract] [Full Text] [Related]
2. Subcellular localisation of pMEK has a different prognosis in locally advanced head and neck cancer treated with concomitant radiochemotherapy.
Gomez-Millan J; Pajares B; Perez-Villa L; Carnero A; Alvarez M; De Luque V; Rivas F; Trigo JM; Toledo MD; Alba E; Medina JA
BMC Cancer; 2016 Oct; 16(1):829. PubMed ID: 27793200
[TBL] [Abstract] [Full Text] [Related]
3. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.
Ho AL; Grewal RK; Leboeuf R; Sherman EJ; Pfister DG; Deandreis D; Pentlow KS; Zanzonico PB; Haque S; Gavane S; Ghossein RA; Ricarte-Filho JC; DomÃnguez JM; Shen R; Tuttle RM; Larson SM; Fagin JA
N Engl J Med; 2013 Feb; 368(7):623-32. PubMed ID: 23406027
[TBL] [Abstract] [Full Text] [Related]
4. The CDKN2A and MAP kinase pathways: molecular roads to primary oral mucosal melanoma.
Hsieh R; Nico MM; Coutinho-Camillo CM; Buim ME; Sangueza M; Lourenço SV
Am J Dermatopathol; 2013 Apr; 35(2):167-75. PubMed ID: 23000904
[TBL] [Abstract] [Full Text] [Related]
